Gavin MacBeath
CEO, Principal Financial Officer, Principal Accounting Officer & DirectorDr. Gavin MacBeath, Ph.D., serves as CEO & Director of TScan Therapeutics, Inc. from May 24, 2023 and serves as its Principal Financial Officer & Principal Accounting Officer since September 2, 2026 and served as its Interim Principal Financial Officer since July 21, 2023 until 2023. Dr. MacBeath was Acting CEO & Chief Scientific and Operations Officer of TScan Therapeutics, Inc. from March 28, 2023 to May 24, 2023. Dr. MacBeath was Chief Scientific & Operations Officer of TScan Therapeutics, Inc. from June 01, 2022 to March 28, 2023. Dr. MacBeath was Chief Scientific Officer of TScan Therapeutics, Inc. from December 2018 to June 01, 2022. Dr. MacBeath was Chief Scientific Officer at Abpro Corporation since March 2017 until July 2018. Dr. MacBeath was Co-Founder of Merrimack Pharmaceuticals, Inc. ab[pand served as its Senior Director and the Head of Translational Research. At Merrimack, Dr. MacBeath is responsible for leading the MM-121 research team and creating its general strategy for predictive medicine. He continues to direct a research lab at Harvard Medical School in the Department of Systems Biology. He has pioneered the development of protein microarray technology. Dr. MacBeath was an Associate Professor in the Department of Chemistry and Chemical Biology at Harvard University. He is also interfacing protein microarray technology with high-throughput screening to extend the field of chemical genomics. Dr. MacBeath has experience in academia and the biotechnology industry, with expertise in systems biology, drug discovery, translational research, companion diagnostics and clinical development of early-stage programs. He has an extensive scientific background and expertise in developing new technologies as evidenced by his achievements in both academia and in the clinic. His scientific leadership is be invaluable as advance antibody programs under best-in-class DiversImmuneTM industrial biochemistry platform across large indications including ophthalmology, autoimmunity and immune-oncology. He served as Member of Scientific Advisory Board of Merrimack Pharmaceuticals, Inc. He has been a Member of the Scientific Advisory Board at Aushon BiosyStems, Inc. since September 2010. He is an associate Member of the Broad Institute of MIT and Harvard. Dr. MacBeath received his B.Sc.(Hons.) degree in Genetics from the University of Manitoba in 1991 and his Ph.D. in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute in 1997, training with Professor Donald Hilvert. Dr. MacBeath began his career in academia, where he served as the first fellow at Harvard’s Bauer Center for Genomics Research and as Lecturer and Principal Investigator at Harvard Medical School. He completed postdoctoral training with Dr. Stuart Schreiber at Harvard University.
公司職務
- 公司名稱TScan Therapeutics, Inc.股票代碼TCRX職務CEO, Principal Financial Officer, Principal Accounting Officer & Director共事同僚
- SRStephen Richard BiggarIndependent Chair of the Board
- SJStephen J. ElledgeCo-Founder & Chairman of Scientific Advisory Board
- TKTomasz KulaCo-Founder & Member of Advisory Board
- ZZZoran ZdraveskiChief Legal & Strategy Officer and Company Secretary
- AHAnn HargravesChief Human Resources Officer
- KDKatina DortonIndependent Director
